242 related articles for article (PubMed ID: 31415646)
1. Evaluation of canine 2D cell cultures as models of myxomatous mitral valve degeneration.
Tan K; Markby G; Muirhead R; Blake R; Bergeron L; Fici G; Summers K; Macrae V; Corcoran B
PLoS One; 2019; 14(8):e0221126. PubMed ID: 31415646
[TBL] [Abstract][Full Text] [Related]
2. Culture and characterisation of canine mitral valve interstitial and endothelial cells.
Liu MM; Flanagan TC; Lu CC; French AT; Argyle DJ; Corcoran BM
Vet J; 2015 Apr; 204(1):32-9. PubMed ID: 25747697
[TBL] [Abstract][Full Text] [Related]
3. Reciprocal interactions between mitral valve endothelial and interstitial cells reduce endothelial-to-mesenchymal transition and myofibroblastic activation.
Shapero K; Wylie-Sears J; Levine RA; Mayer JE; Bischoff J
J Mol Cell Cardiol; 2015 Mar; 80():175-85. PubMed ID: 25633835
[TBL] [Abstract][Full Text] [Related]
4. Development and Evaluation of a Tissue-Engineered Fibrin-based Canine Mitral Valve Three-dimensional Cell Culture System.
Liu MM; Flanagan TC; Jockenhovel S; Black A; Lu CC; French AT; Argyle DJ; Corcoran BM
J Comp Pathol; 2018 Apr; 160():23-33. PubMed ID: 29729718
[TBL] [Abstract][Full Text] [Related]
5. Morphological changes to endothelial and interstitial cells and to the extra-cellular matrix in canine myxomatous mitral valve disease (endocardiosis).
Han RI; Clark CH; Black A; French A; Culshaw GJ; Kempson SA; Corcoran BM
Vet J; 2013 Aug; 197(2):388-94. PubMed ID: 23465752
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis and abundance of Bcl-2 family and transforming growth factor β1 signaling proteins in canine myxomatous mitral valves.
Surachetpong S; Jiranantasak T; Rungsipipat A; Orton EC
J Vet Cardiol; 2013 Sep; 15(3):171-80. PubMed ID: 23816827
[TBL] [Abstract][Full Text] [Related]
7. Comparative pathology of human and canine myxomatous mitral valve degeneration: 5HT and TGF-β mechanisms.
Oyama MA; Elliott C; Loughran KA; Kossar AP; Castillero E; Levy RJ; Ferrari G
Cardiovasc Pathol; 2020; 46():107196. PubMed ID: 32006823
[TBL] [Abstract][Full Text] [Related]
8. Survival of activated myofibroblasts in canine myxomatous mitral valve disease and the role of apoptosis.
Blake RR; Markby GR; Culshaw GJ; Martinez-Pereira Y; Lu CC; Corcoran BM
Res Vet Sci; 2020 Feb; 128():99-106. PubMed ID: 31765842
[TBL] [Abstract][Full Text] [Related]
9. TGF-β phospho antibody array identifies altered SMAD2, PI3K/AKT/SMAD, and RAC signaling contribute to the pathogenesis of myxomatous mitral valve disease.
McNair AJ; Markby GR; Tang Q; MacRae VE; Corcoran BM
Front Vet Sci; 2023; 10():1202001. PubMed ID: 37908840
[TBL] [Abstract][Full Text] [Related]
10. Dysregulation of valvular interstitial cell let-7c, miR-17, miR-20a, and miR-30d in naturally occurring canine myxomatous mitral valve disease.
Yang VK; Tai AK; Huh TP; Meola DM; Juhr CM; Robinson NA; Hoffman AM
PLoS One; 2018; 13(1):e0188617. PubMed ID: 29315310
[TBL] [Abstract][Full Text] [Related]
11. TGF-β-induced PI3K/AKT/mTOR pathway controls myofibroblast differentiation and secretory phenotype of valvular interstitial cells through the modulation of cellular senescence in a naturally occurring in vitro canine model of myxomatous mitral valve disease.
Tang Q; Markby GR; MacNair AJ; Tang K; Tkacz M; Parys M; Phadwal K; MacRae VE; Corcoran BM
Cell Prolif; 2023 Jun; 56(6):e13435. PubMed ID: 36869852
[TBL] [Abstract][Full Text] [Related]
12. Defining the Role of the miR-145-KLF4-αSMA Axis in Mitral Valvular Interstitial Cell Activation in Myxomatous Mitral Valve Prolapse Using the Canine Model.
Yang VK; Moyer N; Zhou R; Carnevale SZ; Meola DM; Robinson SR; Li G; Das S
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338749
[TBL] [Abstract][Full Text] [Related]
13. Activation of the Interleukin-33/ST2 Pathway Exerts Deleterious Effects in Myxomatous Mitral Valve Disease.
Garcia-Pena A; Ibarrola J; Navarro A; Sadaba A; Tiraplegui C; Garaikoetxea M; Arrieta V; Matilla L; Fernández-Celis A; Sadaba R; Alvarez V; Gainza A; Jover E; López-Andrés N
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669101
[TBL] [Abstract][Full Text] [Related]
14. Developmental pathways and endothelial to mesenchymal transition in canine myxomatous mitral valve disease.
Lu CC; Liu MM; Clinton M; Culshaw G; Argyle DJ; Corcoran BM
Vet J; 2015 Dec; 206(3):377-84. PubMed ID: 26586213
[TBL] [Abstract][Full Text] [Related]
15. Comparative transcriptomic profiling of myxomatous mitral valve disease in the cavalier King Charles spaniel.
Markby GR; Macrae VE; Corcoran BM; Summers KM
BMC Vet Res; 2020 Sep; 16(1):350. PubMed ID: 32967675
[TBL] [Abstract][Full Text] [Related]
16. Human myxomatous mitral valve prolapse: role of bone morphogenetic protein 4 in valvular interstitial cell activation.
Sainger R; Grau JB; Branchetti E; Poggio P; Seefried WF; Field BC; Acker MA; Gorman RC; Gorman JH; Hargrove CW; Bavaria JE; Ferrari G
J Cell Physiol; 2012 Jun; 227(6):2595-604. PubMed ID: 22105615
[TBL] [Abstract][Full Text] [Related]
17. Comparison of cellular changes in Cavalier King Charles spaniel and mixed breed dogs with myxomatous mitral valve disease.
Lu CC; Liu MM; Culshaw G; French A; Corcoran B
J Vet Cardiol; 2016 Jun; 18(2):100-9. PubMed ID: 26860643
[TBL] [Abstract][Full Text] [Related]
18. Interstitial cells from dogs with naturally occurring myxomatous mitral valve disease undergo phenotype transformation.
Disatian S; Ehrhart EJ; Zimmerman S; Orton EC
J Heart Valve Dis; 2008 Jul; 17(4):402-11; discussion 412. PubMed ID: 18751470
[TBL] [Abstract][Full Text] [Related]
19. Mitral valve endothelial cells secrete osteoprotegerin during endothelial mesenchymal transition.
Songia P; Branchetti E; Parolari A; Myasoedova V; Ferrari G; Alamanni F; Tremoli E; Poggio P
J Mol Cell Cardiol; 2016 Sep; 98():48-57. PubMed ID: 27338002
[TBL] [Abstract][Full Text] [Related]
20. Emerging pathogenic mechanisms in human myxomatous mitral valve: lessons from past and novel data.
Hulin A; Deroanne C; Lambert C; Defraigne JO; Nusgens B; Radermecker M; Colige A
Cardiovasc Pathol; 2013; 22(4):245-50. PubMed ID: 23261354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
